Medtech Go-to-Market Strategy: Evidence, Buying Committees and the Launch Plan

Medical device companies usually have the harder half of go-to-market solved before they start: the product works and the clinical case is real. The half that stalls launches is commercial. Who inside a hospital decides, what evidence each of them accepts, how the money moves through budgets and tenders, and whether to sell direct or through distributors. I have planned launches inside pharma at Johnson & Johnson, sold diagnostics into hospitals and clinics through lab networks across the Gulf, and built go-to-market plans for B2B technology companies. Medtech sits between those worlds, and the plan below borrows from both.

This guide is for founders, commercial leaders and investors in medtech, in vitro diagnostics and connected devices, whether the market is the United States, Europe or the Middle East.

Step 1: Decide the segment and the clinical setting

"Hospitals" is not a segment. A device for cardiac catheterisation labs in tertiary hospitals has a different buyer, budget cycle and evidence bar from a point-of-care test for primary care clinics. Pick the first segment on four criteria:

Clinical need that is felt, not inferred. Clinicians describe the problem in their own words without prompting.
A measurable economic effect inside the buyer's budget: shorter procedure time, fewer readmissions, fewer repeat tests, lower consumable cost, more throughput.
Reachable decision makers. A handful of departments or a known buying group, not the whole health system.
Reference potential. Early adopters whose names open doors in the segment.

Write an ideal customer profile for the institution (size, case volume, ownership, payer mix, existing equipment) and for the champion inside it (specialty, role, what success looks like for them personally).

Pitfall: launching to every setting at once because the product "works everywhere". It dilutes evidence, sales effort and references.

Step 2: Build the evidence the buying committee will accept

Medtech buyers do not share one definition of proof. A launch plan needs an evidence map with a row per stakeholder:

Stakeholder	What they ask	Evidence that answers it
Clinical champion	Does it improve outcomes or workflow for my patients?	Clinical data, peer publications, hands-on evaluation, peer references
Department head	Does it fit our pathway and our case mix?	Workflow studies, training plan, service and uptime commitments
Procurement and supply chain	Is it compliant, available and priced within the framework?	Regulatory clearance, tender documentation, total cost of ownership
Finance and value analysis committee	What is the budget impact and payback?	Health economic model, case for capital or consumables, comparator pricing
Biomedical engineering and IT	Will it integrate, and can we maintain it?	Technical specifications, interoperability, cybersecurity documentation, service model
Infection control, quality and risk	Is it safe and reprocessable?	Risk documentation, instructions for use, post-market surveillance plan
Payers (where reimbursement applies)	Is it covered, and under which code?	Reimbursement pathway, coding guidance, coverage evidence

Build the evidence in the order the committee meets it, not in the order your R&D team finds interesting. A health economic model is often the piece that unlocks the purchase and the piece most start-ups build last.

Pitfall: evidence that proves clinical superiority but says nothing about budget impact. Value analysis committees reject excellent devices for that reason every week.

Step 3: Map the buying process and the money

Every target institution buys through a process. Learn it before the first sales call:

Capital versus consumables. Capital equipment goes through annual budget cycles and committees; consumables and reagents through contracts and frameworks. Many successful medtech models move cost from capital to per-use.
Tenders and frameworks. Public hospitals and many private groups in the Gulf, Europe and Egypt buy through tenders. Know the tender calendar, the qualification requirements, the registration needed to bid, and who writes the specifications. Specifications are often influenced a year before the tender is published.
Group purchasing. In the US, group purchasing organisations and integrated delivery networks set contract access. In the Gulf, government procurement bodies and large private groups play the same role.
Evaluations and trials. Most committees want a hands-on evaluation. Design it with success criteria agreed in advance, a defined period and a named decision at the end.
Reimbursement. Where the device changes how a procedure is coded or paid, the reimbursement pathway is part of go-to-market, not an afterthought.

Draw the process for your first segment as a timeline with the decision gates, the documents required at each gate and the person who owns it.

Step 4: Choose the route to market

Direct, distributor or hybrid is the most consequential medtech decision after segment choice.

Direct gives control of the clinical conversation, pricing and data, and demands capital, local entities and a trained field team. It suits concentrated markets with high-value capital or specialist consumables.
Distributors bring registration, logistics, tender presence and relationships, especially across the Gulf where each country has its own authority and often requires a local agent. The costs are margin, loss of customer data and dependence on the distributor's priorities.
Hybrid models, with your clinical specialists supporting the distributor's sales team and your marketing owning the demand creation, are common in the Middle East and often the right first step.

Whatever the route, keep three things in-house: the clinical education, the customer evidence and the data. A distributor who owns all three owns your market.

Pitfall: choosing a distributor because they are enthusiastic rather than because they already sell to the department you target and have a plan to grow your line within 12 months.

Step 5: Position for each stakeholder, with one core story

Device positioning fails when the clinical message is the only message. Write one core story, then a proof-led version for each committee member. The clinician hears outcomes and workflow; finance hears payback and budget impact; IT hears integration and security; procurement hears compliance and total cost. The words change, the story does not. This is the same discipline I used at Janssen, where one core campaign for Simponi was adapted for each market rather than rewritten.

Test the messages with real stakeholders before launch. Ten structured conversations with a champion, a department head and a procurement lead will save a quarter of guesswork.

Step 6: Plan the launch sequence

A medtech launch runs in three phases, and the first begins long before clearance.

Pre-launch (12 to 18 months before): segment and ideal customer profile; evidence map and the studies to fill it; health economic model; regulatory and registration path per country; reimbursement strategy; key opinion leader identification and advisory board; distributor selection and contracts where relevant; pricing and contracting model; tender calendar for the first markets.

Launch (clearance to month six): limited market release with reference sites and agreed evaluation criteria; clinical training and certification for users; sales enablement built from the evidence map; congress presence and peer-to-peer events; publications and case studies from reference sites; digital presence that answers each stakeholder's questions, including searchable clinical and technical documentation.

Scale (month six onwards): expand to the next segment or country; convert evaluations to contracts; build a customer success function for installed base, uptime and consumable pull-through; collect real-world evidence; feed outcomes back into the health economic model and the sales story.

Give each phase a small set of measures: pipeline by stage and institution, evaluations started and converted, time from first contact to contract, reference sites secured, installed base, consumable revenue per site.

Step 7: Market to the committee, not only to the clinician

Digital marketing for medtech works when it mirrors the buying committee:

Searchable technical and clinical content, because biomedical engineers, procurement officers and clinicians all research online before a meeting.
Account-based marketing for the target institutions: tailored content and outreach for each member of the committee, coordinated with the sales team.
Peer-to-peer programs: webinars, proctoring and site visits with reference users. In devices, the most persuasive seller is another user.
Congresses used for structured demonstrations and advisory meetings, not only for the booth.
Automation that tracks every stakeholder's engagement by account and tells the sales team who to call next.

Do this within medical device promotion rules in each market: advertise only cleared indications, substantiate every performance claim, handle complaints and adverse events through the quality system, and respect procurement rules on hospitality and gifts.

The pitfalls that stall medtech launches

Clinical proof without economic proof. The device is loved and not bought.
No tender strategy. The specification was written around a competitor before you arrived.
Distributor as strategy. Signing a distributor is not a go-to-market plan.
Evaluations without exit criteria. Free trials that never end.
Launching everywhere. Three segments and four countries at once, with one clinical specialist.
Selling the device, not the outcome. Buyers fund fewer complications, more throughput and lower cost per case.
Marketing to clinicians only. The committee has six members and five of them never read a journal article.

A short checklist before launch

Have we chosen one first segment and written the institutional and champion profiles?
Does the evidence map have a credible answer for every committee member, including a health economic model?
Do we know the buying process, the tender calendar and the budget cycle in our first markets?
Is the route to market decided, and do we keep education, evidence and data in-house?
Is there one core story with a proof-led version per stakeholder, tested with real buyers?
Are reference sites, training and customer success planned before the first sale?
Are the launch measures set, with a baseline?

Frequently asked questions

What is a medtech go-to-market strategy?

A medtech go-to-market strategy is the plan for taking a medical device or diagnostic to its first customers: the segment and clinical setting, the evidence each member of the buying committee needs, the purchasing and tender process, the route to market (direct, distributor or hybrid), stakeholder positioning, the launch sequence and the measures of progress.

Should a medical device start-up sell direct or through distributors?

It depends on market concentration, product value and capital. Direct suits concentrated markets and high-value products where control of the clinical conversation matters. Distributors suit fragmented or multi-country markets such as the Gulf, where registration and local presence are required. A hybrid, with the company owning clinical education, evidence and data, is often the right first step.

How long does a medtech launch take?

Commercial preparation should start 12 to 18 months before clearance, because evidence, health economics, registration, tender calendars and distributor contracts all have long lead times. From clearance, a limited release with reference sites typically runs six months before scaling to the next segment or country.

If you are preparing a device or diagnostics launch, see how I support medtech companies as a healthcare marketing expert, or read the sector-neutral go-to-market strategist page for B2B launches. For the Gulf specifically, see Middle East pharma and medtech market entry.